
Quest Diagnostics (DGX) Stock Forecast & Price Target
Quest Diagnostics (DGX) Analyst Ratings
Bulls say
Quest Diagnostics is well positioned in the healthcare industry, with strong core trends, outpacing revenue, adjusted EPS and AOI estimates, and increased volumes through recent partnerships. The company's clinical labs and diagnostic testing services remain a critical component in the treatment decision process, and its expansion into new markets and partnerships with organizations like FMS and Corewell show potential for continued growth. However, the company's premium valuation and potential risks such as decelerating volumes and increasing reimbursement headwinds suggest a balanced risk/reward profile, and we maintain a Hold rating.
Bears say
Quest Diagnostics is facing strong competition and may struggle with growing its revenue in the future. Although the company has potential growth opportunities in its Co-Lab and Corewell segments, they have yet to fully materialize and may not meet revenue targets as expected. Additionally, the company's focus on automation and AI may lead to further cost savings, but it remains to be seen if these initiatives will have a significant impact on overall revenue.
This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Quest Diagnostics (DGX) Analyst Forecast & Price Prediction
Start investing in Quest Diagnostics (DGX)
Order type
Buy in
Order amount
Est. shares
0 shares